What a Pancreatic Cancer Breakthrough Tells Insurers About Expert Medical Opinions
A drug that scientists are calling “cancer’s equivalent of breaking the four-minute mile” is nearing regulatory approval. Daraxonrasib targets a protein that drives nearly all pancreatic tumors — as well as many lung and colon cancers — and in a late-stage pivotal trial, it nearly doubled median survival in patients with metastatic pancreatic cancer from […]